Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma.

Plasma arginine depletion was confirmed at endpoint in BCT-100-treated mice, although tumor arginine depletion did not reach statistical significance due to high variability between animals (Supplementary Fig. 5 C).

also in 111,027 other papers